ClinicalTrials.Veeva

Menu

Therapeutic Drug Monitoring of Teicoplanin in Children

S

Shandong University

Status

Enrolling

Conditions

Bacterial Infections

Treatments

Drug: Teicoplanin-PMMA

Study type

Observational

Funder types

Other

Identifiers

NCT03933748
2019_Teicoplanin_001

Details and patient eligibility

About

In this study, the therapeutic drug monitoring of teicoplanin is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then we analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of teicoplanin in Chinese children.

Enrollment

500 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Teicoplanin was administered intravenously;
  • Teicoplanin was used for therapeutic purposes;
  • Age:≤18 years;
  • Clinician confirms and plans to diagnose the patient with gram-positive coccus infection;
  • Patients with therapeutic concentration monitoring of teicoplanin.

Exclusion criteria

  • Teicoplanin was administered non-intravenously;
  • Teicoplanin was used for prophylactic purposes;
  • Patients without therapeutic concentration monitoring of teicoplanin;
  • Patients who die within 24 hours of the use of teicoplanin;
  • The blood concentrations of the patient was not approved by the quality control center.

Trial contacts and locations

1

Loading...

Central trial contact

Wei Zhao, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems